Kelly Yap

Kelly Yap

Auto-generated profile, based on publicly available information

Kelly Yap

Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JLJennifer Liu
Jennifer Liu
EGEutiquio Gutierrez
Eutiquio Gutierrez
ATAbhay Tiwari
Abhay Tiwari
SPSimran Padam
Simran Padam
DLDaneng Li
Daneng Li
MSMina Sedrak
Mina Sedrak
Cancer is a disease associated with aging. As the US population ages, the number of older adults with cancer is projected to dramatically increase. Despite this, older adults remain vastly underrepresented in research that sets the standards for cancer treatments and, consequently, clinicians struggle with how to interpret data from clinical trials and apply them to older adults in practice. A combination of system, clinician, and patient barriers bar opportunities for trial participation for many older patients, and strategies are needed to address these barriers at multiple fronts, five of which are offered here. This review highlights the need to (1) broaden eligibility criteria, (2) measure relevant end points, (3) expand standard trial designs, (4) increase resources (e.g., institutional support, interdisciplinary care, and telehealth), and (5) develop targeted interventions (e.g., behavioral interventions to promote patient enrollment). Implementing these solutions requires a substantial investment in engaging and collaborating with community-based practices, where the majority of older patients with cancer receive their care. Multifaceted strategies are needed to ensure that older patients with cancer, across diverse healthcare settings, receive the highest-quality, evidence-based care.

Verified
Journal Article
Open access
PDF file
NSNicholas Salgia
Nicholas Salgia
EPErrol J. Philip
Errol J. Philip
MZMohammadbagher Ziari
Mohammadbagher Ziari
KYKelly Yap
Kelly Yap
SPSumanta K Pal
Sumanta K Pal
The treatment of metastatic renal cell carcinoma (mRCC) has rapidly evolved; however, the progress made in the field is heavily contingent upon timely and efficient accrual to clinical trials. While a substantial proportion of accrual occurs at tertiary care centers, community sites are playing an increasing role in patient recruitment. In this article, we discuss strategies to optimize collaborations between academic and community sites to facilitate clinical research. Further, as the role of biomarker discovery has become increasingly important in tailoring therapy, we will discuss opportunities to bridge diverse accrual sites for the purpose of translational research.